跳至主要内容
临床试验/NCT02112877
NCT02112877已完成不适用

VIRTUS Safety and Efficacy of the Veniti Vici™ Venous Stent System (Veniti, Inc.) When Used to Treat Clinically Significant Chronic Non-malignant Obstruction of the Iliofemoral Venous Segment

Boston Scientific Corporation40 个研究点 分布在 7 个国家目标入组 200 人开始时间: 2014年6月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
40
主要终点
Number of Participants With Major Adverse Events (MAE)

研究概览

简要总结

This is a prospective, multi-center, single arm, non-randomized study to define safety and efficacy of the Veniti Vici™ Venous Stent System in relation to pre-defined Objective Performance goals. A maximum of 200 patients at up to 45 centers worldwide will be enrolled. Thirty (30) feasibility patients will be enrolled at approximately 7-10 centers and 170 pivotal patients will be enrolled at approximately 45 centers worldwide. The follow-up period is 36 months.

详细描述

The objective of this prospective study is to assess the safety and efficacy of the Veniti Vici™ Venous Stent System in achieving patency of the target venous lesion in patients who present with clinically significant chronic non-malignant obstruction of the iliofemoral venous outflow tract.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Number of Participants With Major Adverse Events (MAE)

时间窗: 30 days

The primary safety endpoint for this study will be a composite endpoint of any major adverse event (MAE) within 30 days, as adjudicated by a Clinical Events Committee.

Percentage of Participants That Demonstrated Primary Patency

时间窗: 12 months post-intervention

The primary effectiveness endpoint is the primary patency rate at 12 months post-intervention, defined as freedom from occlusion by thrombosis, freedom from surgical or endovascular intervention on target vessel which are found to have re-stenosis or stent occlusion to maintain patency, and freedom from in-stent stenosis more than 50% by venogram.

次要结局

  • Number of Participants With Improvement in Venous Clinical Severity Score (VCSS)(12 months post-intervention)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (40)

Loading locations...

相似试验

VIRTUS: An Evaluation of the Vici™ Venous Stent... | 临床试验